The manufacturer of temsirolimus (Wyeth) was invited to submit evidence for this single technology appraisal (STA) in November 2009.
In January 2010, the manufacturer informed NICE that it would not be making an evidence submission. The manufacturer subsequently confirmed this in August 2010. Given the rarity of the condition, the complex clinical management of mantle cell lymphoma and the large number of comparator regimens used in the single randomised clinical trial, the manufacturer did not believe that an adequate assessment of the clinical and cost effectiveness of temsirolimus would be possible.
NICE has therefore terminated this single technology appraisal.